Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Arjun Mittra
- Target Recruit Count
- 24
- Registration Number
- NCT06269978
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06266832
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Nicholas DeVito, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06268015
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 96
- Registration Number
- NCT06259058
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06256328
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 73
- Registration Number
- NCT06245356
- Locations
- 🇫🇷
Institut du Cancer d'Avignon, Avignon, France
🇫🇷CHU Jean Minjoz, Besançon, France
🇫🇷Centre Hospitalier de Cholet, Cholet, France
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 41
- Registration Number
- NCT06225999
- Locations
- 🇯🇵
National Cancer Center Hospital East (003), Kashiwa, Chiba, Japan
🇯🇵Chiba University Hospital (015), Chiba, Japan
🇯🇵Chiba Cancer Center (011), Chiba, Japan
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06225622
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT06210360
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 33
- Registration Number
- NCT06208462
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.